JPM vs NMS

JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.

The deterministic health profile is critically weak, highlighted by a Piotroski F-Score of 1/9, which heavily penalizes the fund's fundamental health rating. While the fund has shown strong price appreciation over the last 1-3 years and maintains a respectable dividend yield of 6.54%, the technical trend has collapsed to 10/100, suggesting a bearish reversal. As a municipal income fund, traditional corporate metrics like the Altman Z-Score and Graham Number are not applicable, but the current price is trading at the ceiling of its 52-week range ($12.20 vs $12.25 high). The combination of poor deterministic health scores and a bearish technical outlook offsets the positive historical price performance.